当前位置：
X-MOL 学术
›
Pediatr. Blood Cancer
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Late effects in pediatric Hodgkin lymphoma survivors after uniform treatment with ABVD with or without radiotherapy
Pediatric Blood & Cancer ( IF 3.2 ) Pub Date : 2021-08-25 , DOI: 10.1002/pbc.29293 Abhenil Mittal 1 , Sainath Bhethanabhotla 1 , Shuvadeep Ganguly 1 , Sreenivas Vishnubhatla 2 , Rajesh Khadgawat 3 , Chetan Patel 4 , Anant Mohan 5 , Ahitagni Biswas 6 , Sameer Bakhshi 1
Pediatric Blood & Cancer ( IF 3.2 ) Pub Date : 2021-08-25 , DOI: 10.1002/pbc.29293 Abhenil Mittal 1 , Sainath Bhethanabhotla 1 , Shuvadeep Ganguly 1 , Sreenivas Vishnubhatla 2 , Rajesh Khadgawat 3 , Chetan Patel 4 , Anant Mohan 5 , Ahitagni Biswas 6 , Sameer Bakhshi 1
Affiliation
ABVD (doxorubicin, bleomycin,vinblastine, and dacarbazine) is not a standard regimen in children due to concerns regarding late effects. However, no studies have evaluated long-term toxicities of ABVD in children.
中文翻译：
儿童霍奇金淋巴瘤幸存者在采用 ABVD 联合或不联合放疗后的迟发效应
ABVD（多柔比星、博来霉素、长春碱和达卡巴嗪）不是儿童的标准治疗方案，因为担心迟发效应。然而，没有研究评估 ABVD 对儿童的长期毒性。
更新日期：2021-09-24
中文翻译：
儿童霍奇金淋巴瘤幸存者在采用 ABVD 联合或不联合放疗后的迟发效应
ABVD（多柔比星、博来霉素、长春碱和达卡巴嗪）不是儿童的标准治疗方案，因为担心迟发效应。然而，没有研究评估 ABVD 对儿童的长期毒性。
京公网安备 11010802027423号